Shardul Amarchand Mangaldas & Co. Advised Aragen Life Sciences And Existing Promoters On Share Sale And Subscription Transaction With Quadria Capital Entities
Shardul Amarchand Mangaldas & Co. Advised Aragen Life Sciences And Existing Promoters On Share Sale And Subscription Transaction With Quadria Capital Entities
Shardul Amarchand Mangaldas & Co. advised Aragen Life Sciences Limited, Reddy Investment Trust, and Mr. Davinder Singh Brar in a transaction involving the subscription to shares of Aragen Life Sciences Limited by Quadria Capital and the purchase of shares by Quadria Capital from the existing promoters and Goldman Sachs.
The transaction, valued at approximately USD 100 million, will result in Quadria Capital acquiring a minority stake in Aragen, at an approximate valuation of USD 1.4 billion.
The investment proposes to support Aragen’s strategic expansion of its capabilities and infrastructure, enabling the company to meet the growing demand for outsourcing services from innovators in the US and Europe.
The transaction team at Shardul Amarchand Mangaldas & Co. was led by Partners Karun Prakash and Sangamitra Sankaraiah, Senior Associates Aditya Yadav and Hitakshi Mahendru, and Associate Janavi Venkatesh.
The due diligence team was led by Partners Karun Prakash, Sangamitra Sankaraiah, and Kriti Kaushik, Principal Associate Namrata Ramachandran, Senior Associates Aditya Yadav and Hitakshi Mahendru, and Associates Sukoon Dinodia, Janavi Venkatesh, Bhavna Hemrajani, Aagam Jain, Istuti Kapoor, Sanskriti Nigam, and Alice Sharma.
